baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

CytomX Therapeutics Inc/ US23284F1057 /

2024-04-25 10:00:00 PM	Chg. -0.0300	Volume	Bid10:00:01 PM	Ask10:00:01 PM	High	Low
1.6000USD	-1.84%	286,316 Turnover: 420,508.8907	1.5500Bid Size: 600	1.9800Ask Size: 200	1.6400	1.5800

GlobeNewswire 04-08 CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Dire...

GlobeNewswire 04-03 CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engag...

GlobeNewswire 03-21 CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

GlobeNewswire 03-18 CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Col...

GlobeNewswire 03-11 CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update

GlobeNewswire 03-05 Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expande...

GlobeNewswire 03-04 CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024

GlobeNewswire 02-27 CytomX Therapeutics to Present at Upcoming March Investor Conferences

GlobeNewswire 01-24 CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Dru...

GlobeNewswire 01-12 CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference

GlobeNewswire 01-04 CytomX Therapeutics Outlines 2024 Company Priorities and Milestones

GlobeNewswire 2023-12-21 CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire 2023-11-07 CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire 2023-11-01 CytomX Therapeutics to Present at Upcoming November Investor Conferences

GlobeNewswire 2023-10-31 CytomX Therapeutics to Report Third Quarter 2023 Financial Results on November 7, 2023

GlobeNewswire 2023-10-30 CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at t...

GlobeNewswire 2023-10-18 CytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 a...

GlobeNewswire 2023-09-05 CytomX Therapeutics to Present at Upcoming September Investor Conferences

GlobeNewswire 2022-03-23 CytomX Therapeutics Announces Retirement of Frederick W. Gluck from Board of Directors

GlobeNewswire 2022-03-17 CytomX Therapeutics to Present Updated Preclinical Data for Conditionally Activated Cytokine Program...

GlobeNewswire 2022-03-01 CytomX Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Busine...

GlobeNewswire 2022-02-28 CytomX Therapeutics to Present at Cowen 42nd Annual Healthcare Conference

GlobeNewswire 2022-02-22 CytomX Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022

GlobeNewswire 2022-02-16 CytomX Therapeutics Announces New Employment Inducement Grants

CytomX Therapeutics Inc/ US23284F1057 /

If you wish to receive reply to your feedback, please provide your email address.